Introduction
Treatment of heart failure with preserved ejection fraction (HFpEF) is a large unmet need based on its current and projected prevalence, unfavourable outcomes, and lack of effective therapies.
1,2
Importantly, health-related quality of life (HRQoL) is as impaired in patients with HFpEF as in those with heart failure with reduced ejection fraction (HFrEF), 3 and worse health status is associated with higher rates of mortality and hospital readmission. 4 Improving the health status (symptoms, function and quality of life) of patients with HFpEF is thus an important goal of treatment. 5, 6 To date, pharmacological interventions have had limited success in improving the health status of patients with HFpEF. 7, 8 Soluble guanylate cyclase (sGC)-derived generation of cyclic guanosine monophosphate (cGMP) is impaired in HFpEF 9 and may represent a novel treatment target. sGC stimulators have the capacity for direct, nitric oxide (NO)-independent stimulation of sGC, and could be of potential benefit in HFpEF. The once daily oral sGC stimulator, vericiguat, was studied in the SOCRATES phase 2 programme in two parallel trials in patients with HFrEF and in patients with HFpEF within 4 weeks after heart failure (HF) decompensation. Results of the SOCRATES-REDUCED study have been published 10 and the main results of the SOCRATES-PRESERVED study are reported in a separate publication. 11 Here we report patient-reported outcomes (PROs), including the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the generic HRQoL measure EQ-5D, as pre-specified exploratory endpoints in the SOCRATES-PRESERVED study.
12 A 5-point change in KCCQ scores is considered clinically significant. 13, 14 Not only does the KCCQ capture the impact of HF on patients' health status with high validity, reliability and sensitivity, but scores are also associated with subsequent mortality, hospital admissions and costs. 4, 14, 15 
Methods

Study design and patient population
SOCRATES-PRESERVED was a randomized, double-blind, placebo-controlled trial in 25 countries. The design of the study has been published previously. 12 In brief, SOCRATES-PRESERVED enrolled patients ≥18 years of age with symptomatic chronic HF randomized upon clinical stabilization at the time of discharge or up to 4 weeks after HF decompensation. Eligible patients had New York Heart Association (NYHA) class II-IV symptoms, left ventricular (LV) ejection fraction (EF) ≥ 45%, left atrial enlargement as assessed by echocardiography, and elevated natriuretic peptide level-B-type natriuretic peptide (BNP) ≥ 100 pg/mL or N-terminal pro-brain natriuretic peptide (NT-proBNP) ≥ 300 pg/mL if in sinus rhythm, or BNP ≥ 200 pg/mL or NT-proBNP ≥ 600 pg/mL if in atrial fibrillation. Randomization was stratified by sinus rhythm vs. atrial fibrillation. Patients were randomized 1:1:1:1:1 to 12 weeks of treatment with one of four different dose regimens of vericiguat (1.25, 2.5, 5, and 10 mg target doses) or matching placebo, followed by a safety follow-up period of 4 weeks. Titration to target dose was according to blood pressure values and tolerability at week 2 (Visit 2), and week 4 (Visit 3) after randomization as described previously. This study has been approved by the national and/or local ethics committees of the participating institution and regulatory agencies, and complied with the Declaration of Helsinki. All patients provided written informed consent for their participation in the study.
A major protocol violation occurred during the conduct of the study due to an erroneous software update of the drug dispensation system (Interactive voice/web response system, IxRS), resulting in incorrect doses of study drug being dispensed. This aspect has been reported in detail.
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Health-related quality of life assessment
Health-related quality of life was a pre-specified exploratory outcome, designed to supplement the two primary endpoints of change in log NT-proBNP and left atrial volume (LAV). 11 PROs were measured using the disease-specific KCCQ and the generic EQ-5D three-level questionnaire (EQ-5D-3 L). The KCCQ comprises 23 items that are summarized in two summary scores: clinical summary score (CSS), including physical functioning and symptom domains, and the overall summary score (OSS), which additionally includes quality of life and social limitation domains. 16 All scales range from 0 to 100, with higher scores representing improved health status. The EQ-5D three-level version comprises two parts, the first containing five questions related to mobility, self-care, usual activities, pain/discomfort and anxiety/depression, with three categories of response. Responses were scored using US and UK societal value weights 17 with the US index score being presented. In addition, patients also completed the EQ-5D visual analogue scale (VAS), in which they were asked to assess their own health on a 0-100 scale with zero representing the 'worst imaginable health state'. The PROs were assessed at randomization and at weeks 4, 8, and 12, and at a premature termination visit, if one occurred. PRO instruments were self-completed by patients at the start of the clinic visit before any other procedure or assessment. Derivation of scores, including handling of missing answers to questionnaires, was done according to scoring instructions (both KCCQ and EQ-5D). Completely missing questionnaires were not imputed in the main analysis.
The PROs were supported by clinician-based outcomes assessments, including NYHA class, and an assessment of six signs and symptoms of congestion (dyspnoea, orthopnoea, fatigue, jugular venous distension, rales, and oedema). Additionally, the three domains orthopnoea, jugular venous distension, and oedema, were combined in the composite congestion score (CCS).
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Statistical analysis
Descriptive summaries of PRO endpoints and responder analyses were pre-specified in the protocol and statistical analysis plan, while statistical testing was specified post hoc and hence P-values are not multiplicity adjusted and should also be considered "exploratory". Data are summarized by mean ± standard deviation (SD), mean ± standard error of the mean (SEM), or frequencies as indicated. Between-group comparisons of changes in quality of life [KCCQ and EQ-5D domains] were performed by Kruskal-Wallis tests and Wilcoxon rank-sum tests. Dose-response associations were assessed with linear regression models, with baseline health status scores included as covariates. Responder analyses for the KCCQ were based on the proportion of patients achieving a small, but clinical relevant difference of 5 points, a moderate improvement of 10 points, or a large improvement of 20 points based upon previous studies defining a clinically important threshold of change. 13, 14 
CSS, clinical summary score; EQ-5D, 5-dimension EuroQol questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; PLS, physical limitation score; OSS, overall summary score; TSS, total symptom score; NYHA, New York Heart Association; VAS, visual analogue scale; KCCQ-CSS is calculated from the mean of PLS and TSS.
Missing data were assumed to be missing at random and no imputation of missing values was performed. Sensitivity analyses were conducted where missing values were imputed by the last available observation carried forward (LOCF) for patients who did not die. Patients who discontinued treatment were asked to complete a premature termination visit. Information from this visit, if available, was used for LOCF imputation. Patients who died were either omitted, or a worst case imputation (i.e. imputing zero for KCCQ scores and lowest possible value for EQ-5D scores, or artificial worst class of 5 for NYHA and worst score of 10 for CSS) was used, as given in Supplementary material online, Figure S3 and Table S4 ). All analyses are shown for the full analysis set, excluding patients with doses assigned incorrectly by the trial drug dispensation system.
Results
Of the 477 randomized patients, a total of 429 patients went into the full analysis set excluding patients with incorrectly assigned doses. Forty-eight patients (5 mg group, n = 20; 10 mg group, n = 28) who erroneously received lower than planned study drug doses were excluded from analyses. Baseline values of demographic, clinical, and KCCQ and EQ-5D domains were well balanced across treatment arms ( Table 1 ; Supplementary material online, Table S1 ). Low KCCQ and EQ-5D scores reflect the severe disease burden shortly after an episode of HF decompensation. The key domains of the KCCQ and EQ-5D increased more in the highest dose vericiguat treatment arm than in the placebo arm. Table 2 summarizes PRO scores in KCCQ and EQ-5D domains at baseline and at 4, 8, and 12 weeks (end of treatment). Figure 1 shows the mean changes in KCCQ and EQ-5D domains over time, by randomized treatment regimen.
. 
Disease-specific health status (KCCQ)
In all groups, including placebo, improvements in patients' reported disease-specific health status were observed within the first 4 weeks of treatment when patients were still in a period of recovery from the heart failure decompensation event and dose titration. However, the 5 and 10 mg target doses of vericiguat were associated with continued improvements over time, resulting in larger increases from baseline at 12 weeks [CSS: 19.3 ± 16.3 (mean ± SD) in the 10 mg arm compared with 10.2 ± 20.0 in the placebo arm, Figure 1 ]. To assess the effect attributable to the period following the final dose titration, a post hoc assessment of weeks 4-12 was performed. The mean change in KCCQ-CSS from week 4 to week 12 in the 5 and 10 mg arms was 7.4 and 6.2, compared with 0.5 in placebo-treated patients, (P = 0.0046 and 0.0465, respectively; see Supplementary material online, Figure S1 ). A conservative adjustment of changes from baseline to 12 weeks by the changes seen between baseline and week 4 in the two highest dose groups also led to more similar results in the 5 and 10 mg arms (Supplementary material online, Table S2 ).
To better characterize the change in health status with increasing doses of vericiguat, we adjusted for differences in baseline PRO scores and examined dose dependency in a linear model. The KCCQ-CSS, the physical limitation sub-domain, and the OSS suggested dose-dependent improvements in patients' health status (Supplementary material online, Table S3 ).
Observed improvements were strongest in the KCCQ physical function domain [17.2 ± 19.1 (mean ± SD)] at 12 weeks in the 10 mg arm compared with 4.5 ± 21.6 in the placebo arm and driven by items requiring moderate to higher levels of exertion. Symptom CSS, clinical summary score; EQ-5D, 5-dimension EuroQol questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; OSS, overall summary score; PLS, physical limitation score; TSS, total symptom score; VAS, visual analogue scale. a Due to the titration schedule, patients in the 5 mg arm and 10 mg arm received the same titration up to week 4. At week 4, the first up-titration to10 mg was possible in the respective treatment arm.
improvement was driven by items related to shortness of breath, orthopnoea, and feet/ankle/leg swelling ( Figure 2) . Sensitivity analyses using imputation for missing values [applying last observation carried forward (LOCF) for non-death cases and omitting death cases, or applying LOCF for non-death cases and zero/worst case for death cases] demonstrated consistent improvement in KCCQ and EQ-5D scores (Supplementary material online, Table S4 ). Similar improvements in KCCQ-CSS and KCCQ-physical limitation domain as well as EQ-5D US index score were seen across pre-specified subgroups and no subgroups were identified with relevant differences in response (Supplementary material online, Figure S2 ). To help render the health status improvements more interpretable, we examined the proportion of patients at 12 weeks with clinically meaningful improvement in KCCQ scores. Using a previously defined minimal clinically important difference (MCID) threshold of ≥5 points, the KCCQ-CSS improved in 82% of patients on vericiguat 10 mg vs. 59% on placebo, suggesting a number needed to treat (NNT) of 4.4 for one additional patient to feel noticeably better compared with placebo at 12 weeks (Figure 3 ; Supplementary material online, 
Generic health status (EQ-5D)
Meaningful improvement compared with placebo was also observed in the generic EQ-5D US index score and the EQ-5D VAS for the 5 mg and 10 mg arms ( Figure 1 ; Table 2 ), which continued beyond 4 weeks (Supplementary material online, Figure S1 ).
Comparison with placebo showed a difference of 0.045 for the 5 mg group and 0.072 for the 10 mg group in changes from baseline of the EQ-5D US index score at 12 weeks. Similarly, the change from baseline in the EQ-5D VAS at 12 weeks was ∼5 points higher for the higher dose arms (5.5 for 5 mg and 5.2 for 10 mg) compared with placebo. 16 .
NYHA class and a numerically smaller proportion of patients with deterioration to 0% in the 10 mg arm, compared with placebo; Figure 4A ). Sensitivity analyses using imputation for missing values showed generally consistent results (Supplementary material online, Figure S3 ). Moreover, there were improvements in CCS, with a numerically larger proportion of patients with improved CCS at 12 weeks in the 10 mg arm, compared with placebo ( Figure 4B ; and Supplementary material online, Figure S3 for missing value imputation). Jugular venous distension showed the strongest response among CCS items, whereas both proportions of patients with improvements as well as deteriorations in physician-assessed oedema slightly increased in the 10mg arm ( Figure 4C ).
Discussion
The KCCQ and EQ-5D, mean changes relative to placebo were above previously defined levels of MCID. 13, 19 At the level of individual patients, the responder analyses suggest as few as three to five patients need to be treated with the higher doses of vericiguat for one to feel moderately or substantially better. The magnitude of observed responses to vericiguat in the KCCQ-CSS and -OSS is larger than in previous interventional studies of oral drugs in HF, where improvements have been in the region of 1-3 points, which is below the magnitude considered to be clinically meaningful. For example, in HFpEF, spironolactone in TOPCAT was associated with a mean improvement in KCCQ-OSS at 4 months of 1.5 (whole trial) and 2.1 in the Americas. 8 Prior to the availability of the TOPCAT results, a meta-analysis of eight trials across medication classes showed no difference overall, nor any signal of meaningful effect, in any HF medication class for HFpEF patients. 7 In the SHIFT randomized trial of patients with HFrEF, ivabradine was associated with an improvement in HRQoL. Notably, the mean increase in KCCQ-CSS and -OSS at 12 months in ivabradine-treated patients compared with placebo did not exceed 2.4 and 1.8, respectively, although the incidence of clinical events (cardiovascular death or hospital admission for HF) was inversely associated with KCCQ scores. 20 In contrast to pharmacological trials, exercise and diet interventions have shown improvement in quality of life and functional endpoints. A meta-analysis of exercise intervention trials (n = 5) in patients with HFpEF reported an improvement of approximately 9 points on the Minnesota Living with Heart Failure (MLWHF) scale, which is of similar magnitude to that seen for the 10 mg vericiguat arm in this trial. 7 Similar results were shown for calorie restriction in obese patients with HFpEF. 21 The changes in the KCCQ-CSS with vericiguat were driven by improvements in the physical limitation domain items of the KCCQ, showing that patients reported less limitation in their ability to perform activities associated with daily living. Improvements were shown in individual items of the physical limitation score capturing self-care (dressing, bathing), and other daily activities (walking 100 yards, chores, climbing stairs, and hurrying as if to catch a bus). The differences were greater in activities requiring moderate to higher physical exertion. Whilst the difference in total symptom score (TSS) for the 10 mg arm was not significant, there were nominal improvements in the items related to frequency of shortness of breath and orthopnoea. The greater difference in physical limitation improvement in the 10 mg vericiguat arm relative to the TSS suggests a different underlying mechanism of vericiguat compared with renin-angiotensin-aldosterone system blockade that was associated with some improvement in the TOPCAT trial. 8 The generic EQ-5D domain scores and the VAS, which reflect patients' own assessment of their global health, while less specific to the aspects of health important to patients with HF, are also in line with the KCCQ results and extend assessment to the potential impact of vericiguat on broader aspects of HRQoL. Summary score improvements for the 5 and 10 mg arms were at a meaningful level (defined as 0.04 and 5 points for the US index score and the VAS, respectively).
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Previous attempts to enhance cGMP levels did not improve patient-reported outcomes.
22 -24 The NEAT-HF study of isosorbide mononitrate (ISMN) in patients with HFpEF 23 and a recent trial of sildenafil 22 in patients with pulmonary hypertension due to HFpEF did not show improvements in KCCQ. This may reflect the different NO-independent mechanism of direct sGC stimulation with vericiguat compared with ISMN or cGMP elevation via inhibition of its phosphodiesterase type 5-mediated breakdown, which still relies on sGC stimulation. There was also no improvement reported with ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and beta-blockers. 7 In the largest trial in this meta-analysis, Aldo-DHF, treatment with spironolactone did not change MLWHF-assessed quality of life at 1 year. 25 Likewise, LCZ696 did not improve KCCQ scores, despite decreasing NT-proBNP at 12 weeks and reducing LAV at 36 weeks, together with a noted improved NYHA class at the later time point. 26 In contrast, while NT-proBNP and LAV were chosen as primary endpoints in the current study, both were unaffected by vericiguat treatment at 12 weeks, yet there was strong improvement in PROs. The disconnect between improvement in health status and no change in NT-proBNP is of particular interest, given that both NT-proBNP changes and KCCQ-CSS have separately been shown to be associated with clinical outcomes. 4 Previous studies with pharmacological interventions that decreased NT-proBNP have shown no, or less than clinically meaningful, improvements in HRQoL and have not improved outcomes. This suggests the need to continue further exploration of promising new mechanisms. Although no alternative mechanisms underlying the health status improvement upon vericiguat treatment have been proved by our data, the concordant trend to increase e ′ and other echocardiographic changes 11 will be the focus of further studies at rest and under exercise.
Limitations of this study include the post hoc definition of analyses, the limited sample size distributed across five randomized arms, and the exclusion of patients with incorrectly assigned doses. The eligibility criteria of this phase 2 study limit generalizability, as patients were recruited within a 4 week period after an HF event in which the study population experience a continuing but heterogeneous recovery from the qualifying event. This may contribute to the observed heterogeneity across dose arms, in particular the differences between the 5 mg and 10 mg arms despite the same up-titration during the initial 4 week titration period. This observation triggered additional post hoc analyses of the 4-12 week time frame (i.e. only after the 10 mg up-titration option had been reached), in order to explore dose-related differences between arms during this more stable treatment period. The possibility of spurious chance findings arising from patients remaining on a more beneficial natural trajectory cannot be excluded. Patients spent only 8-10 weeks on the target dose of 10 or 5 mg, respectively. Although the similar magnitude of improvement in the 5 mg arm compared with the 10 mg arm after the final titration step may suggest the possibility that doses close to the maximum effective doses were reached, further improvements in PRO with higher doses cannot be excluded. There were no functional endpoints collected such as 6 min walk distance, peak VO 2 , or hand grip strength, which could have added to the interpretation of the PRO. Although there were no differences in the primary endpoints, NT-proBNP and LAV, at 12 weeks in the vericiguat group compared with the placebo group, post hoc analyses of a pre-defined exploratory endpoint domain suggested increases in KCCQ and EQ-5D, above defined MCID, in the higher dose arms (5 mg and 10 mg). These exploratory data generate the hypothesis of potentially clinically significant improvements in patients' disease-specific and overall health status, which require prospective validation in subsequent studies. Future studies should seek to understand the mechanism of potential improvements in health status without NT-proBNP decreases at 12 weeks, to confirm the effects in HRQoL and functional status over longer periods of time, and how they translate and contribute to other components of clinically relevant outcomes in patients with HFpEF.
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